JP2020173186A - Method for determining excess or deficiency of calcium intake - Google Patents
Method for determining excess or deficiency of calcium intake Download PDFInfo
- Publication number
- JP2020173186A JP2020173186A JP2019075681A JP2019075681A JP2020173186A JP 2020173186 A JP2020173186 A JP 2020173186A JP 2019075681 A JP2019075681 A JP 2019075681A JP 2019075681 A JP2019075681 A JP 2019075681A JP 2020173186 A JP2020173186 A JP 2020173186A
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- intake
- deficiency
- subject
- urine collection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 129
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 79
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 30
- 230000007812 deficiency Effects 0.000 title claims abstract description 20
- 210000002700 urine Anatomy 0.000 claims abstract description 85
- 239000011777 magnesium Substances 0.000 claims abstract description 35
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940109239 creatinine Drugs 0.000 claims abstract description 13
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 206010006956 Calcium deficiency Diseases 0.000 claims abstract description 8
- 230000001502 supplementing effect Effects 0.000 claims abstract description 3
- 229960005069 calcium Drugs 0.000 description 65
- 230000002485 urinary effect Effects 0.000 description 32
- 235000013305 food Nutrition 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 7
- 230000000378 dietary effect Effects 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- 241000243321 Cnidaria Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FDKAAIFOPLCYAM-UHFFFAOYSA-M C(C(O)C)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[Ca+] Chemical compound C(C(O)C)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[Ca+] FDKAAIFOPLCYAM-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001019450 Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 / VKM B-1768 / DS2) Isocitrate dehydrogenase [NADP] Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- -1 calcined calcium) Chemical compound 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- VEJCUEBBRSCJRP-UHFFFAOYSA-L calcium;hydron;phosphonato phosphate Chemical compound [Ca+2].OP(O)(=O)OP([O-])([O-])=O VEJCUEBBRSCJRP-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本発明は、尿中のマグネシウム／クレアチニン比を指標として、対象者のカルシウム摂取量の過不足を判定する方法に関する。 The present invention relates to a method for determining excess or deficiency of calcium intake of a subject using the magnesium / creatinine ratio in urine as an index.
日本人にとって、カルシウムは、依然としてどの年代においても不足している栄養素である。カルシウム不足は、骨や歯が弱くなるだけでなく、高齢者や特に閉経期の女性においては骨粗鬆症のリスクファクターとなる。自身のカルシウム摂取量もしくは不足量を客観的かつ簡便に推定する技術へのニーズが高まっている。
対象者のカルシウム摂取量を推定する方法として、主に、対象者の尿から推定する方法と、食事記録から推定する方法の２つが挙げられる。
For the Japanese, calcium is still a nutrient deficient in all ages. Calcium deficiency not only weakens bones and teeth, but is also a risk factor for osteoporosis in the elderly and especially in menopausal women. There is an increasing need for a technique for objectively and easily estimating one's own calcium intake or deficiency.
There are mainly two methods for estimating the calcium intake of the subject, a method of estimating from the subject's urine and a method of estimating from the dietary record.
尿から推定する方法として、これまで、２４時間蓄尿中のカルシウム濃度と、採尿前の連続した４日間の食事記録から算出した平均１日カルシウム摂取量との間には相関関係があるものの、その相関係数は０．２７６と低いことが報告されている（非特許文献１）。また、２４時間蓄尿中のカルシウム量を体重で除した値と、食物摂取頻度調査（ＦＦＱｇ法）を基に算出した平均のカルシウム摂取量との間には相関関係がない（相関係数Ｒ＝−０．１１９３）こと、２４時間蓄尿中のマグネシウム量を体重で除した値と、食物摂取頻度調査を基に算出した平均のカルシウム摂取量との間にも相関関係がない（相関係数Ｒ＝０．１０８９）ことが知られている（非特許文献２）。 As a method of estimating from urine, there is a correlation between the calcium concentration during 24-hour urine storage and the average daily calcium intake calculated from the dietary records for 4 consecutive days before urine collection. It has been reported that the correlation coefficient is as low as 0.276 (Non-Patent Document 1). In addition, there is no correlation between the value obtained by dividing the amount of calcium in 24-hour urine storage by body weight and the average amount of calcium intake calculated based on the food intake frequency survey (FFQg method) (correlation coefficient R =). -0.1193) There is no correlation between the value obtained by dividing the amount of magnesium in 24-hour urine storage by body weight and the average amount of calcium intake calculated based on the food intake frequency survey (correlation coefficient R). = 0.1089) is known (Non-Patent Document 2).
１８〜３３歳の若い女性を対象としたヒト介入試験において、２４時間蓄尿中のカルシウム量を体重で除した値と、過去４日間の食事記録から算出した平均１日カルシウム摂取量を体重で除した値との間には、相関がある（Ｒ＝０．４０２、ｐ＜０．００１）ことが知られている（非特許文献３）。しかしながら、女性は閉経期、エストロゲンの分泌が低下することにより、骨などからのカルシウム流出が増え、カルシウムの吸収と排泄のバランスが変化するため、若い女性のみを対象とした試験は、閉経期または高齢の女性にまで外挿できない。また、カルシウムの吸収と排泄のバランスは、性差や年齢差があることも知られている。より広い年代の男女に外挿できるカルシウム摂取量の推定方法が望まれる。 In a human intervention study of young women aged 18 to 33 years, the value obtained by dividing the amount of calcium in 24-hour urine storage by body weight and the average daily calcium intake calculated from the dietary records of the past 4 days were divided by body weight. It is known that there is a correlation (R = 0.402, p <0.001) with the values obtained (Non-Patent Document 3). However, during menopause, decreased estrogen secretion increases calcium outflow from bones and changes the balance between calcium absorption and excretion. Therefore, studies targeting only young women are conducted during menopause or It cannot be externalized even to elderly women. It is also known that there are gender and age differences in the balance between calcium absorption and excretion. A method for estimating calcium intake that can be extrapolated to men and women of a wider age is desired.
尿中成分濃度は食事や水分摂取、発汗などの影響を受けやすく、そのときの尿量によって大きく変動するため、２４時間蓄尿を用いてカルシウムの摂取量を推定する方法が一般的に用いられる。２４時間蓄尿は対象者の負担が大きいため、随時尿を用いて対象者の負担を軽減したカルシウム摂取量を推定する方法もある。随時尿を用いてカルシウムの摂取量を推定する場合、前述のとおり、尿中成分濃度は食事や水分摂取、発汗などの影響を受けやすく、尿の濃さによって成分濃度が大きく変動するため、尿の濃度を補正する必要があり、その手段として、同時に測定したクレアチニン値との比率を求めるクレアチニン補正が行われている。 Since the urinary component concentration is easily affected by food, water intake, sweating, etc. and varies greatly depending on the urine volume at that time, a method of estimating calcium intake using 24-hour urine storage is generally used. Since the burden on the subject is heavy for 24-hour urine collection, there is also a method of estimating the calcium intake that reduces the burden on the subject by using urine at any time. When estimating calcium intake using urine at any time, as mentioned above, the urinary component concentration is easily affected by diet, water intake, sweating, etc., and the component concentration fluctuates greatly depending on the urine concentration. It is necessary to correct the concentration of creatinine, and as a means for this, creatinine correction is performed to obtain the ratio with the creatinine value measured at the same time.
食事記録からカルシウム摂取量を推定する方法として、文部科学省が調査・公表しており、約２２００種の食品について食品可食部１００ｇあたりの栄養素が記載された「日本食品標準成分表」が一般的に用いられる。本発明において用いた算出方法としては、食事記録などにより判定した食品別の摂取量と、「日本食品標準成分表」とを照らすことにより、対象者が摂取した栄養素を算出した。 As a method of estimating calcium intake from meal records, the Ministry of Education, Culture, Sports, Science and Technology has investigated and published, and the "Standard Tables of Food Composition in Japan", which describes the nutrients per 100 g of food edible portion for about 2200 kinds of foods, is common. Used for As the calculation method used in the present invention, the nutrients ingested by the subject were calculated by comparing the intake amount for each food determined by meal records and the like with the "Standard Tables of Food Composition in Japan".
上記のとおり、カルシウム摂取量の推定方法として、従来は２４時間蓄尿を用いることが一般的であるが、それでは対象者の負担が大きい。一方、食事記録からカルシウム摂取量を推定する方法もあるが、従来は食事記録をとらなければならず、こちらも対象者の負担が大きい。 As described above, as a method for estimating calcium intake, it has been common to use 24-hour urine collection in the past, but this puts a heavy burden on the subject. On the other hand, there is also a method of estimating calcium intake from meal records, but in the past, meal records had to be taken, which also puts a heavy burden on the subject.
本出願人は、随時尿中のマグネシウムの多寡を指標として、採尿前の食事記録から推定したカルシウム摂取量との間に高い相関があることを見出し、本発明を完成した。 The applicant has completed the present invention by finding that there is a high correlation with the calcium intake estimated from the dietary record before urine collection, using the amount of magnesium in urine as an index at any time.
本発明は、対象者の負担を抑え、簡便に対象者のカルシウム摂取量を推定し、対象者のカルシウム摂取量の過不足を判定する方法を提供することを課題とする。 An object of the present invention is to provide a method for suppressing the burden on the subject, easily estimating the calcium intake of the subject, and determining the excess or deficiency of the calcium intake of the subject.
本発明の課題を解決するための手段は、以下の通りである。
１．対象者から採取した随時尿中のマグネシウム／クレアチニン比を指標として、対象者のカルシウム摂取量を推定する、カルシウム摂取量の過不足判定方法。
２．前記カルシウム摂取量が、採尿日を始点として採尿前３月期間内から選択される期間内に摂取したカルシウム量である、１．に記載のカルシウム摂取量の過不足判定方法。
３．１．又は２．に記載のカルシウム摂取量の過不足判定方法を用いて、対象者のカルシウム不足量を算出し、カルシウム不足量を補うための経口組成物を提供するシステム。
The means for solving the problem of the present invention is as follows.
1. 1. A method for determining excess or deficiency of calcium intake, in which the calcium intake of a subject is estimated using the magnesium / creatinine ratio in urine collected from the subject as an index.
2. 1. The calcium intake is the amount of calcium ingested within a period selected from the period of 3 months before urine collection starting from the day of urine collection. The method for determining excess or deficiency of calcium intake described in 1.
3.1. Or 2. A system for calculating a calcium deficiency amount of a subject using the method for determining excess or deficiency of calcium intake described in the above, and providing an oral composition for supplementing the calcium deficiency amount.
本発明のカルシウム摂取量の過不足判定方法は、随時尿を用いてカルシウム摂取量を推定することができるため、対象者の負担が小さい。対象者は、自宅で採尿キットなどを用いて簡便な方法でサンプルを採取することが可能であり、このサンプルを郵送することによってカルシウム摂取量の過不足判定結果が得られる。さらに、得られた過不足判定結果から不足量を算出することにより、不足量を補うための経口組成物の提供を受けることが可能となる。 In the method for determining excess or deficiency of calcium intake of the present invention, the calcium intake can be estimated using urine at any time, so that the burden on the subject is small. The subject can collect a sample at home by a simple method using a urine collection kit or the like, and by mailing this sample, an excess / deficiency determination result of calcium intake can be obtained. Further, by calculating the deficiency amount from the obtained excess / deficiency determination result, it becomes possible to receive an oral composition for compensating for the deficiency amount.
以下、本発明について詳細に説明する。
本発明のカルシウム摂取量の過不足判定方法は、随時尿中のマグネシウム／クレアチニン比を指標とすることを特徴とする。
随時尿を採取するタイミングとして、特に限定されるものではないが、１日の中で最初に食事を摂取するまでに採取することが好ましく、起床後すぐに採取する第一尿が特に好ましい。
Hereinafter, the present invention will be described in detail.
The method for determining excess or deficiency of calcium intake of the present invention is characterized in that the magnesium / creatinine ratio in urine is used as an index at any time.
The timing of collecting urine at any time is not particularly limited, but it is preferable to collect urine before the first meal in the day, and the first urine collected immediately after waking up is particularly preferable.
本発明者らは、随時尿中のマグネシウム／クレアチニン比とカルシウム摂取量とが相関を有することを見出し、下記近似式を得た。
（近似式）
カルシウム摂取量[ｍｇ／１０００ｋｃａｌ]
＝（ａ）×（随時尿中のマグネシウム／クレアチニン比[ｍｇ／ｇ]）＋（ｂ）
（ａ）は１〜２が好ましく、１．１〜１．６がさらに好ましい。（ｂ）は１００〜３００が好ましく、１５０〜２６０がさらに好ましい。
The present inventors have found that the magnesium / creatinine ratio in urine and the calcium intake have a correlation from time to time, and obtained the following approximate formula.
(Approximate formula)
Calcium intake [mg / 1000kcal]
= (A) × (magnesium / creatinine ratio in urine [mg / g] at any time) + (b)
(A) is preferably 1 to 2, and more preferably 1.1 to 1.6. (B) is preferably 100 to 300, more preferably 150 to 260.
この近似式に基づき、対象者の随時尿中のマグネシウム／クレアチニン比の値から、対象者のカルシウム摂取量を推定することができる。また、この推定したカルシウム摂取量と、ヒトが１日に必要とするカルシウムの基準量に基づき、カルシウムの過不足を判定することができる。ヒトが１日に必要とするカルシウムの基準量は、特に制限されないが、好適に、厚生労働省が示す「日本人の食事摂取基準」が示す値を挙げることができる。 Based on this approximate expression, the calcium intake of the subject can be estimated from the value of the magnesium / creatinine ratio in the subject's urine at any time. In addition, the excess or deficiency of calcium can be determined based on the estimated calcium intake and the reference amount of calcium required by humans per day. The standard amount of calcium required by humans per day is not particularly limited, but preferably, the value indicated by the "Japanese dietary intake standard" indicated by the Ministry of Health, Labor and Welfare can be mentioned.
上記近似式により推定されるカルシウム摂取量は、採尿日を始点として採尿前３月期間内から選択される期間内に摂取したカルシウム量であることが好ましい。この期間は、採尿日を始点として採尿前３月期間内であれば特に制限されず、例えば、採尿前３月間、採尿前３０日間、採尿前７日間、採尿前３日間、採尿日１日間等から選択することができる。一度の食事内容による変動を抑えるために、ある程度の長さの期間であることが好ましく、採尿日を始点として採尿前３〜３０日間程度であることが好ましい。また、このカルシウム摂取量は、摂取期間内に摂取した１日平均のカルシウム摂取量とすることもできる。 The calcium intake estimated by the above approximate formula is preferably the amount of calcium ingested within a period selected from the period of 3 months before urine collection starting from the urine collection date. This period is not particularly limited as long as it is within the period of 3 months before urine collection starting from the urine collection date. For example, 3 months before urine collection, 30 days before urine collection, 7 days before urine collection, 3 days before urine collection, 1 day before urine collection, etc. You can choose from. In order to suppress fluctuations due to the content of one meal, it is preferable that the period is a certain length, and it is preferably about 3 to 30 days before urine collection starting from the urine collection day. In addition, this calcium intake can be the average daily calcium intake taken during the intake period.
本発明で用いる採尿容器は、病院や検査機関等で実施されている尿検査のために使用される尿中成分の変質を引き起こさない形状、材質であれば特に限定されず用いることができる。採尿容器には、尿中成分の変質を抑制するための安定化剤をあらかじめ添加しておくことが好ましい。ここで、尿中成分の安定化剤として、クエン酸、シュウ酸、塩酸、酒石酸、アスコルビン酸を用いることができ、好適にはクエン酸を用いることができる。採尿容器に尿を定容量加えた際、前記安定化剤の終濃度は、尿中成分を安定化させる観点で０．０１Ｍ〜１Ｍが好ましく、０．０５〜０．５Ｍがさらに好ましい。 The urine collection container used in the present invention is not particularly limited as long as it has a shape and material that does not cause deterioration of urine components used for urinalysis performed in hospitals, inspection institutions, and the like. It is preferable to add a stabilizer for suppressing deterioration of urine components to the urine collection container in advance. Here, citric acid, oxalic acid, hydrochloric acid, tartaric acid, and ascorbic acid can be used as the stabilizer of the urinary component, and citric acid can be preferably used. When a constant volume of urine is added to the urine collection container, the final concentration of the stabilizer is preferably 0.01 M to 1 M, more preferably 0.05 to 0.5 M from the viewpoint of stabilizing the urine component.
上記近似式から推定したカルシウム摂取量と、ヒトが１日に必要とするカルシウムの基準量に基づき、対象者のカルシウム不足量を求めることができる。そして、対象者毎に必要な不足量のカルシウムを配合した経口組成物を提供することができ、対象者は１日に必要とするカルシウム量を補うことができる。 Based on the calcium intake estimated from the above approximation formula and the reference amount of calcium required by humans per day, the calcium deficiency amount of the subject can be obtained. Then, it is possible to provide an oral composition containing a required amount of calcium for each subject, and the subject can supplement the amount of calcium required for one day.
本発明で提供する経口組成物は、医薬品（医薬部外品を含む）や、栄養補助食品、栄養機能食品、特定保健用食品、機能性表示食品、病者用食品等の機能性食品、一般的な食品、食品添加剤として用いることができる。継続的な摂取が行いやすいように、例えば、錠剤、カプセル剤、顆粒剤、散剤、丸剤、チュアブル錠、口腔内崩壊錠、ドリンク剤、ゼリー状の形態を有することが好ましい。棒状、板状、グミ状に加工した食品や、一般的な食品形態に添加したものであってもよい。中でも錠剤、カプセル剤の形態が、摂取の簡便さの点から特に好ましい。このような剤形を有する製剤は、慣用法によって調整することができ、カルシウムの放出性を制御した、速放性、徐放性の製剤であってもよい。 The oral composition provided in the present invention includes pharmaceuticals (including non-pharmaceutical products), nutritional supplements, nutritionally functional foods, foods for specified health uses, foods with functional claims, functional foods such as foods for the sick, and general foods. It can be used as a food and food additive. It is preferable to have, for example, tablets, capsules, granules, powders, pills, chewable tablets, orally disintegrating tablets, drinks, and jelly-like forms so that continuous ingestion can be easily performed. Foods processed into rods, plates, gummy candies, or added to general food forms may be used. Of these, the forms of tablets and capsules are particularly preferable from the viewpoint of ease of ingestion. The preparation having such a dosage form can be adjusted by a conventional method, and may be a rapid-release or sustained-release preparation in which the release of calcium is controlled.
本発明の経口組成物に配合するカルシウムとしては、炭酸カルシウム（貝殻未焼成カルシウム、卵殻未焼成カルシウム、造礁サンゴ未焼成カルシウムを含む）、酸化カルシウム（貝殻焼成カルシウム、卵殻焼成カルシウム、造礁サンゴ焼成カルシウムを含む）、水酸化カルシウム、リン酸カルシウム（骨未焼成カルシウム、骨焼成カルシウム、乳清焼成カルシウムを含む）、リン酸三カルシウム、グリセロリン酸カルシウム、クエン酸カルシウム、酢酸カルシウム、グルコン酸カルシウム、ステアリン酸カルシウム、乳酸カルシウム、硫酸カルシウム、塩化カルシウム、水酸化カルシウム、ピロリン酸二水素カルシウム、及びステアロイル乳酸カルシウムからなる群から選ばれる少なくとも１種又は２種以上を組み合わせたものを挙げることができる。 The calcium to be blended in the oral composition of the present invention includes calcium carbonate (including unbaked shell calcium, unbaked eggshell calcium, and unburned reef-building coral), calcium oxide (baked shell calcium, calcined eggshell calcium, reef-building coral). Calcium hydroxide (including calcined calcium), calcium hydroxide, calcium phosphate (including unburned bone calcium, calcined bone calcium, calcined milk boiled calcium), tricalcium phosphate, calcium glycerophosphate, calcium citrate, calcium acetate, calcium gluconate, calcium stearate , At least one selected from the group consisting of calcium lactate, calcium sulfate, calcium chloride, calcium hydroxide, calcium dihydrogen pyrophosphate, and stearoyl calcium lactate, or a combination of two or more thereof.
本発明で提供する経口組成物は、カルシウム以外にも、カルシウムの生体利用率を高めるための補助成分を配合することができ、その他にも例えば、ビタミン、ミネラル、アミノ酸、糖、ポリペプチド、魚油といった栄養素を配合することができる。 In addition to calcium, the oral composition provided in the present invention can contain auxiliary components for increasing the bioavailability of calcium, and other ingredients such as vitamins, minerals, amino acids, sugars, polypeptides, and fish oils can be added. It is possible to mix nutrients such as.
３０〜６０代の１１７名の男女を対象に、食事から摂取したカルシウム、カロリーの量および、尿中のカルシウム（Ｃａ）、マグネシウム（Ｍｇ）、クレアチニン（Ｃｒｅ）濃度を測定した。以降、カルシウムはＣａ、マグネシウムはＭｇ、クレアチニンはＣｒｅと略記する。 The amount of calcium and calories ingested from the diet and the concentrations of calcium (Ca), magnesium (Mg), and creatinine (Cre) in urine were measured in 117 men and women in their 30s and 60s. Hereinafter, calcium is abbreviated as Ca, magnesium is abbreviated as Mg, and creatinine is abbreviated as Cre.
（Ｃａ摂取量）
対象者に、３０日間毎食の食事内容（食品と摂取量）を記録させた。食事記録より判定した食品別の摂取量を、「日本食品標準成分表２０１５年版（七訂）」に照らすことにより、対象者のＣａ摂取量とカロリー摂取量を算出した。
採尿前日の夕食において、Ｃａ摂取量をカロリー摂取量で除して、１０００ｋｃａｌあたりのＣａ摂取量を求め、採尿前日夕食のＣａ摂取量[ｍｇ／１０００ｋｃａｌ]とした。同様に、採尿前３日間ならびに採尿前３０日間の１日Ｃａ摂取量の平均を、１日摂取カロリーの平均で除して、１０００ｋｃａｌあたりのＣａ摂取量を求め、それぞれ、採尿前３日間の平均Ｃａ摂取量[ｍｇ／１０００ｋｃａｌ／ｄａｙ]、採尿前３０日間の平均Ｃａ摂取量[ｍｇ／１０００ｋｃａｌ／ｄａｙ]とした。
(Ca intake)
Subjects were asked to record the dietary content (food and intake) of each meal for 30 days. The Ca intake and calorie intake of the subject were calculated by comparing the intake of each food determined from the dietary record with the "Standard Tables of Food Composition in Japan 2015 (7th edition)".
In the supper on the day before urine collection, the Ca intake was divided by the calorie intake to obtain the Ca intake per 1000 kcal, which was used as the Ca intake [mg / 1000 kcal] in the supper on the day before urine collection. Similarly, the average daily Ca intake for 3 days before urine collection and 30 days before urine collection was divided by the average daily calorie intake to obtain the Ca intake per 1000 kcal, and the average for each of the 3 days before urine collection was obtained. The Ca intake [mg / 1000 kcal / day] and the average Ca intake [mg / 1000 kcal / day] for 30 days before urine collection were used.
（採尿）
対象者に、試験最終日の早朝第一尿（起床後すぐの尿）を１０ｍＬ容量の採尿容器に２本採取させた。
採尿容器２本中１本は、Ｍｇを測定するためのものであり、安定化剤として、終濃度が０．１Ｍとなるよう、あらかじめ安定化剤（クエン酸）を加えた。
採尿容器２本中別の１本は、ＣａおよびＣｒｅを測定するためのものであり、安定化剤を加えなかった。
(Urine collection)
The subjects were asked to collect two bottles of the first urine (urine immediately after waking up) in the early morning on the final day of the test in a 10 mL volume urine collection container.
One of the two urine collection containers is for measuring Mg, and as a stabilizer, a stabilizer (citric acid) was added in advance so that the final concentration was 0.1 M.
Another one of the two urine collection containers was for measuring Ca and Cre, and no stabilizer was added.
（尿中成分の定量）
尿中Ｃａ濃度はシカフィットＣａ試薬（ＣＰＺ−IIIキレート比色法、極東製薬工業株式会社）、尿中Ｍｇ濃度はアクアオートカイノスＭｇ-II試薬（ＩＣＤＨ法、株式会社カイノス）、尿中Ｃｒｅ濃度はシカリキッド−Ｎ ＣＲＥ試薬（酵素法、関東化学株式会社）を用い、検体検査機器（ＡＣＣＵＴＥ ＲＸ キヤノンメディカルシステムズ株式会社）により自動分析した。
分析結果より、尿中のＣａ濃度[ｍｇ／ｍＬ]、Ｍｇ濃度[ｍｇ／ｍＬ]およびＣｒｅ濃度[ｇ／ｍＬ]、Ｃａ／Ｃｒｅ比[ｍｇ／ｇ]、Ｍｇ／Ｃｒｅ比[ｍｇ／ｇ]を算出した。
(Quantification of urinary components)
Urinary Ca concentration is Cikafit Ca reagent (CPZ-III chelate colorimetric method, Far East Pharmaceutical Co., Ltd.), urinary Mg concentration is Aqua Autokinos Mg-II reagent (ICDH method, Kainos Co., Ltd.), urinary Cre concentration Was automatically analyzed by a sample testing device (ACCUTE RX Canon Medical Systems Co., Ltd.) using the Shikarikid-N CRE reagent (enzyme method, Kanto Chemical Co., Inc.).
From the analysis results, Ca concentration [mg / mL], Mg concentration [mg / mL] and Cre concentration [g / mL], Ca / Cre ratio [mg / g], Mg / Cre ratio [mg / g] in urine Was calculated.
（相関係数および近似式）
カルシウム摂取量（採尿前日夕食のＣａ摂取量、採尿前３日間の１日平均Ｃａ摂取量、採尿前３０日間の１日平均Ｃａ摂取量）と、尿中成分（Ｃａ濃度、Ｃａ／Ｃｒｅ比、Ｍｇ濃度ならびにＭｇ／Ｃｒｅ比）との相関係数および近似式を求めた。結果を表１に示す。
Calcium intake (Ca intake for dinner the day before urine collection, average daily Ca intake for 3 days before urine collection, average daily Ca intake for 30 days before urine collection) and urinary components (Ca concentration, Ca / Cre ratio, The correlation coefficient and the approximate expression with the Mg concentration and Mg / Cre ratio) were obtained. The results are shown in Table 1.
〔結果〕
（実施例１）
尿中Ｍｇ／Ｃｒｅ比と採尿前日夕食のＣａ摂取量との間に相関関係があり、相関係数は、Ｒ＝０．２５３、統計値Ｐ＝０．００６、近似式「Ｃａ摂取量＝１．５２５×尿中Ｍｇ／Ｃｒｅ比＋１８３．８」が得られた。
（実施例２）
尿中Ｍｇ／Ｃｒｅ比と採尿前３日間の１日平均Ｃａ摂取量との間に高い相関関係があり、相関係数は、Ｒ＝０．３８９、統計値Ｐ＝０．００００１、近似式「Ｃａ摂取量＝１．５０７×尿中Ｍｇ／Ｃｒｅ比＋２１４．４」が得られた。
（実施例３）
尿中Ｍｇ／Ｃｒｅ比と採尿前３０日間の１日平均Ｃａ摂取量との間に高い相関関係があり、相関係数は、Ｒ＝０．３４３、統計値Ｐ＝０．０００２、近似式「Ｃａ摂取量＝１．１６６×尿中Ｍｇ／Ｃｒｅ比＋２３８．３」が得られた。
（比較例１〜９）
比較例１〜９のとおり、尿中Ｍｇ濃度、尿中Ｃａ濃度、尿中Ｃａ／Ｃｒｅ比は、いずれもＣａ摂取量と相関を示さなかった。
〔result〕
(Example 1)
There is a correlation between the urinary Mg / Cre ratio and the Ca intake of dinner the day before urine collection, and the correlation coefficient is R = 0.253, statistical value P = 0.006, and the approximate formula "Ca intake = 1". .525 x urinary Mg / Cre ratio + 183.8 "was obtained.
(Example 2)
There is a high correlation between the urinary Mg / Cre ratio and the daily average Ca intake for 3 days before urine collection, and the correlation coefficient is R = 0.389, statistical value P = 0.00001, approximate formula " Ca intake = 1.507 x urinary Mg / Cre ratio + 214.4 "was obtained.
(Example 3)
There is a high correlation between the urinary Mg / Cre ratio and the daily average Ca intake for 30 days before urine collection, and the correlation coefficient is R = 0.343, statistical value P = 0.0002, approximate formula " Ca intake = 1.166 x urinary Mg / Cre ratio + 238.3 "was obtained.
(Comparative Examples 1 to 9)
As shown in Comparative Examples 1 to 9, the urinary Mg concentration, the urinary Ca concentration, and the urinary Ca / Cre ratio did not show any correlation with the Ca intake.
実施例１〜３のとおり、尿中Ｍｇ／Ｃｒｅ比とＣａ摂取量との間には高い相関があり、近似式を用いることにより、対象者の尿中Ｍｇ／Ｃｒｅ比から、対象者のＣａ摂取量を従来よりも高い精度で、かつ簡便に推定することができた。 As shown in Examples 1 to 3, there is a high correlation between the urinary Mg / Cre ratio and the Ca intake, and by using an approximate formula, the subject's Ca can be obtained from the subject's urinary Mg / Cre ratio. The intake amount could be estimated more accurately and easily than before.
Claims (3)
A system for calculating a calcium deficiency amount of a subject by using the method for determining excess or deficiency of calcium intake according to claim 1 or 2, and providing an oral composition for supplementing the calcium deficiency amount.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019075681A JP2020173186A (en) | 2019-04-11 | 2019-04-11 | Method for determining excess or deficiency of calcium intake |
| JP2023043925A JP2023075321A (en) | 2019-04-11 | 2023-03-20 | Excess/deficiency determination method of calcium intake |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019075681A JP2020173186A (en) | 2019-04-11 | 2019-04-11 | Method for determining excess or deficiency of calcium intake |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043925A Division JP2023075321A (en) | 2019-04-11 | 2023-03-20 | Excess/deficiency determination method of calcium intake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2020173186A true JP2020173186A (en) | 2020-10-22 |
Family
ID=72831013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019075681A Pending JP2020173186A (en) | 2019-04-11 | 2019-04-11 | Method for determining excess or deficiency of calcium intake |
| JP2023043925A Pending JP2023075321A (en) | 2019-04-11 | 2023-03-20 | Excess/deficiency determination method of calcium intake |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043925A Pending JP2023075321A (en) | 2019-04-11 | 2023-03-20 | Excess/deficiency determination method of calcium intake |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP2020173186A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022168745A1 (en) * | 2021-02-03 | 2022-08-11 | 株式会社健康再生研究所 | Dietary habit evaluation system and dietary habit evaluation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996004554A1 (en) * | 1994-08-01 | 1996-02-15 | S.A.N.D. Institute (Aust) Pty. Limited | Urinary test strip for determining calcium loss |
| JP2011107113A (en) * | 2009-11-20 | 2011-06-02 | Yoshitane Kojima | Method for inspecting elements in body tissue and food with fluorescent x-ray analyzer |
| JP2014039536A (en) * | 2012-07-24 | 2014-03-06 | Nippon Formula Feed Mfg Co Ltd | Beef cattle feed and breeding method |
-
2019
- 2019-04-11 JP JP2019075681A patent/JP2020173186A/en active Pending
-
2023
- 2023-03-20 JP JP2023043925A patent/JP2023075321A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996004554A1 (en) * | 1994-08-01 | 1996-02-15 | S.A.N.D. Institute (Aust) Pty. Limited | Urinary test strip for determining calcium loss |
| JP2011107113A (en) * | 2009-11-20 | 2011-06-02 | Yoshitane Kojima | Method for inspecting elements in body tissue and food with fluorescent x-ray analyzer |
| JP2014039536A (en) * | 2012-07-24 | 2014-03-06 | Nippon Formula Feed Mfg Co Ltd | Beef cattle feed and breeding method |
Non-Patent Citations (3)
| Title |
|---|
| 土田満: "ナトリウム,カリウム,カルシウム,リン,マグネシウム,亜鉛の摂取量と糞中,尿中排せつ量または血清中濃度との", 栄養学雑誌, vol. 49, no. 1, JPN6022049565, February 1991 (1991-02-01), pages 35 - 44, ISSN: 0004925395 * |
| 志賀 瓏郎: "羊の周産期における血清,尿および乳汁のカルシウム,リン,マグネシウム濃度の変化", 日畜会報, vol. 66, no. 3, JPN6022049566, 25 March 1995 (1995-03-25), pages 267 - 273, ISSN: 0004925396 * |
| 河辺聡子: "ミネラルの尿中排泄量と食物摂取頻度調査成績との関係", 川崎医療福祉学会誌, vol. 16, no. 2, JPN6022049564, 25 January 2007 (2007-01-25), pages 291 - 297, ISSN: 0004925394 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022168745A1 (en) * | 2021-02-03 | 2022-08-11 | 株式会社健康再生研究所 | Dietary habit evaluation system and dietary habit evaluation method |
| JP7185976B1 (en) * | 2021-02-03 | 2022-12-08 | 株式会社健康再生研究所 | Eating habit evaluation system and eating habit evaluation method |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023075321A (en) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lynch | The effect of calcium on iron absorption | |
| Koo et al. | Maternal calcium supplementation and fetal bone mineralization | |
| Engberink et al. | Dietary acid load and risk of hypertension: the Rotterdam Study | |
| Theobald | Dietary calcium and health | |
| Dewey | Nutrition, growth, and complementary feeding of the brestfed infant | |
| Rivera et al. | Zinc supplementation improves the growth of stunted rural Guatemalan infants | |
| Araujo et al. | Macronutrient consumption and inadequate micronutrient intake in adults | |
| Park et al. | Calcium from plant sources is beneficial to lowering the risk of osteoporosis in postmenopausal Korean women | |
| Terry et al. | Dietary calcium and vitamin D intake and risk of colorectal cancer: a prospective cohort study in women | |
| Micronutrient Initiative | Zinc and human health: results of recent trials and implications for program interventions and research | |
| Gulati et al. | Effect of high-protein meal replacement on weight and cardiometabolic profile in overweight/obese Asian Indians in North India | |
| Hansen et al. | Energy and nutrient intakes in congenital heart disease | |
| Wynn et al. | Postgraduate symposium positive influence of nutritional alkalinity on bone health: Conference on ‘over-and undernutrition: challenges and approaches’ | |
| Schaefer et al. | Growth and skeletal maturation in children with phenylketonuria | |
| Moore et al. | Effects of average childhood dairy intake on adolescent bone health | |
| Buchowski | Calcium in the context of dietary sources and metabolism | |
| Sales et al. | Inadequate dietary intake of minerals: prevalence and association with socio-demographic and lifestyle factors | |
| Prentice et al. | An appraisal of the adequacy of dietary mineral intakes in developing countries for bone growth and development in children | |
| JP2023075321A (en) | Excess/deficiency determination method of calcium intake | |
| Dąbrowski et al. | Assessing weaning stress–Relations between enamel hypoplasia, δ18O and δ13C values in human teeth obtained from early modern cemeteries in Wroclaw, Poland | |
| Olayiwola et al. | Serum micronutrient status and nutrient intake of elderly Yoruba people in a slum of Ibadan, Nigeria | |
| Fox et al. | Pantothenic acid excretion on three levels of intake | |
| Schoppen et al. | Bone remodelling is not affected by consumption of a sodium-rich carbonated mineral water in healthy postmenopausal women | |
| Fauveau et al. | Limited impact of a targeted food supplementation programme in Bangladeshi urban slum children | |
| Petrenya et al. | No ethnic disparities in nutritional adequacy between the Indigenous Sami and the non-Sami population living in rural Northern Norway—the SAMINOR 2 Clinical Survey |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211221 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221222 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230221 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230320 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240305 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240305 |